Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02284932
• Other study ID #: COPD-20739
• Status: Active, not recruiting
• Phase: N/A
• First received: October 8, 2014
• Last updated: September 7, 2016
• Start date: September 2011
• Est. completion date: September 2018

Study information

• Verified date: September 2016
• Source: Laval University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality.

One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.

Description:

The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle atrophy. Moderate to severe COPD patients (FEV1 under 60% of predicted) and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured in the quadriceps.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 36
• Est. completion date: September 2018
• Est. primary completion date: September 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 55 Years to 75 Years

Eligibility

Inclusion Criteria:

• male

• COPD with an FEV1 of under 60% of predicted

• non-smoker

• between 55 and 75 years old

Exclusion Criteria:

• all inflammatory disease (HIV, cancer, renal and cardiac deficiency)

• hormonal dysregulation

• inferior limb pathology

• neuromuscular pathology

• history of tobacco or alcool abuse

• oxygen dependent

• recent exacerbation (2 months) of the symptoms of COPD

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Atrophy
• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Muscular Atrophy
• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• No specific intervention for this study
No specific intervention for this study

Locations

Country	Name	City	State
Canada	Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Laval University	Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decrease of protein degradation in muscles of wasted COPD patients		At baseline (COPD in a stable state of the disease)	No
Secondary	Increase of protein synthesis in muscles of wasted COPD patients		At baseline (COPD in a stable state of the disease)	No